Skip to main content

Table 4 Hearing loss (dB) 3 months post first fitting compared to baseline: a descriptive analysis of the primary endpoint—PP set

From: Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients

Subgroup

Number

Mean

Std. Dev.

Minimum

Median

Maximum

Placebo

12

29.17

15.05

5.00

30.00

55.00

ACEMg

11

23.64

18.99

− 10.00

20.00

55.00

Flex 20

3

13.33

14.43

5.00

5.00

30.00

Flex 24

6

28.33

15.71

10.00

27.50

50.00

Flex 28

14

28.57

17.59

− 10.00

32.50

55.00

Surgeon 2

16

25.94

14.97

− 10.00

30.00

50.00

Other surgeons

7

27.86

21.96

5.00

20.00

55.00